Are you tired of having to navigate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts and let you focus on…
This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve…
DrugPatentWatch was featured in a recent article by Inc. Magazine. In their coverage of Mark Cuban’s new pharma company, they cited our published interview where Mark Cuban Sounds off on Drug Prices.…
This article was first published by Elinevan Overbeeke, Sissel Michelsen, Mondher Toumi, Hilde Stevens, Mark Trusheim, Isabelle Huys, and StevenSimoens in Drug Discovery Today under a Creative Commons License. Highlights…
This article was originally published by Abdrhman Mahmoud Gamil in World Journal of Advanced Research and Reviews, 2020, 08(03), 337–349 under a Creative Commons Attribution Liscense 4.0. Abstract Procurement is…
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet
1
This article was originally published by Andreas Bender and Isidro Cortes-Ciriano in Drug Discovery Today under a Creative Commons license. Although artificial intelligence (AI) has had a profound impact on…
This article was originally published by Sajna T. in Management Insight, 16(1):38-40 under a creative commons license. Abstract Business enterprises are an important organ of society. The impact of a…
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the world health organization essential medicines list. Some of their key…
We prefer simple flat-rate unrestricted subscriptions — we’ll work on your terms, and with your favorite subscription contract template, to find a solution that fits. If your colleagues would like to…
Here is a copy of the talk I gave at the recent Marcusevans 13th Portfolio Management and Pipeline Optimization for Generics. I cover: How to find and evaluate generic entry…
